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1. Introduction 
Advances in neuroblastoma (NB) treatment over the last three decades have resulted in our 
ability to cure over 70% of children with NB using the current risk-directed therapeutic 
approach. However, until very recently, improvement in treatment outcome was mainly 
attributable to the increased survival of low and intermediate-risk patients. The outcome of 
high-risk NB, especially in children older than 18 months with metastatic disease, remains 
poor. Despite intensive multimodal therapy, over 50% of patients with high-risk NB relapse 
with a dismal long-term outcome (Lau et al., 2004; Santana et al., 2008). While immunotherapy 
has recently increased the post-transplant 2-year event-free survival (EFS) of high-risk NB 
from 46% to 66% (Yu et al., 2010), longer follow-up is required to monitor for late relapse. 
In the last era, children with NB have been offered a wide variety of salvage treatments 
following disease recurrence. Up to half of these patients achieve some response or stable 
disease, and survival after relapse is longer in patients who have received salvage therapy 
(Lau et al., 2004). Chronic NB is also an emerging phenomenon in a subset of patients 
(Kushner et al., 2002). The longer survival after relapse is also likely due to early detection of 
disease recurrence as a result of employing more sophisticated surveillance studies in recent 
years. Furthermore, a proportion of relapsed patients are offered novel agents in phase I/II 
clinical trials. Unfortunately, response to any form of relapsed therapy is rarely sustained. 
Future research leading to a better understanding of the factors influencing the clinical 
course of post-relapse is therefore very important, such that clinicians can select the 
appropriate salvage therapy: to avoid intensive toxic treatment in patients likely to have 
short survival following disease recurrence and to test potentially beneficial therapy. 
2. Clinical presentation of recurrent NB 
Similar to NB at initial diagnosis, the signs and symptoms of relapsed NB reflect the site of 
local and metastatic disease. However, due to the high frequency of metastatic disease at the 
presentation of relapse, symptoms and signs related to distant metastases are significantly 
more common than at diagnosis. Isolated metastatic relapse is found in 60% of patients, 
followed by combined locoregional and metastatic relapse in 32% of patients (Table 1; (Lau 
et al., 2004). Isolated local relapse at the primary tumor site is uncommon (6%) and is 
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generally confined to patients with non-metastatic disease at diagnosis. Bone and/or bone 
marrow disease are present in 75 to 85% of patients with recurrent disease (Kushner et al., 
2002; Lau et al., 2004). As a result, bone pain from osteomedullary metastases represents the 
most common presenting symptom and is reported by 68% of patients with symptomatic 
relapse (Lau et al., 2004). Other symptoms from distant metastases include lethargy, 
irritability, soft tissue mass arising from bony involvement of the calvarium, periorbital 
ecchymosis (raccoon eye), pallor and bruising from bone marrow infiltration and cytopenia, 
and soft tissue mass from lymph node metastases. Depending on the frequency of follow-up 
and the type of investigations used to monitor relapse, 30 to 73% of patients are 
asymptomatic at relapse (Kushner et al., 2009; Lau et al., 2004). 
 
Type of relapse  
Local only 2 
Metastatic only 19 
Local and metastatic 10 
Site of distant relapse  
Bone, bone marrow +/- others 16 
Bone and non-bone marrow 6 
CNS and bone marrow 1 
Bone marrow only 1 
CNS only 2 
Lung only 2 
Lymph node only 1 
Symptoms/Signs   
Yes 22 
No 9 
Time from diagnosis to relapse median 16.1 months (1.7 – 35.8 months) 
Survival post relapse median 8.4 months (0.2 - 51.1 months) 
1-year OS 39% 
3-year OS 11% 
Table 1. Characteristics of 31 relapsed NB patients from a single institution (Lau et al., 2004) 
While central nervous system (CNS) disease is very rare at diagnosis, CNS recurrence has 
been reported in 1 to 5% of all patients with Stage 4 NB (Kellie et al., 1991; Kramer et al., 
2001; Matthay et al., 2003a; Shaw & Eden, 1992). CNS metastases represent 6 to 10% of all 
disease recurrences and 50 to 70% of these CNS recurrences are isolated CNS relapse. This is 
thought to be related to prolonged survival of high-risk NB following intensive systemic 
therapy and the CNS as a sanctuary site for NB. Neuroaxis metastases can be 
intraparenchymal, leptomeningeal, or both. Patients can present with nausea, vomiting, 
headaches, seizures, drowsiness, cranial nerve symptoms, motor weakness/paralysis, and 
back pain (Matthay et al., 2003a). 
Fifty percent of relapses present within 18 months from diagnosis and 77% by 24 months 
(Kushner et al., 2009; Lau et al., 2004; London & Castel et al., 2011; Santana et al., 2008). For 
CNS recurrence, the median time of relapse was 12 to 20 months (Kellie et al., 1991; Kramer 
et al., 2001; Matthay et al., 2003a; Shaw & Eden, 1992). Even though late relapse is 
uncommon, a small number of patients present with first disease recurrence after 5 years 
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and on rare occasions beyond 10 years from diagnosis. Cotterill et al. reported that amongst 
406 patients who were in first remission five years from diagnosis, 3% subsequently 
relapsed and most late relapse patients had Stage 4 disease at diagnosis (Cotterill et al., 
2001). 
3. Risk of disease recurrence 
The ‘events’ considered for analyses of EFS typically include relapse, progression, secondary 
malignancy, or death (from any cause prior to the detection of disease relapse or 
progression). In the majority of NB patients, the first event that patients experience is 
disease relapse or progression. Therefore, factors that are prognostic of EFS are the same risk 
factors that are prognostic for NB relapse. Established risk factors for relapse include older 
age at diagnosis, higher disease stage, MYCN amplification, DNA diploidy, and 
chromosome 1p and 11q aberration. 
Since the early 1970’s, age at diagnosis has been considered a useful factor in predicting the 
occurrence of first relapse, disease progression, or death (Evans et al., 1971), and has 
persisted as highly prognostic despite the discovery of new molecular prognostic factors 
over the last 30 years. Prior to 2005, an age cut-off of 12 months was used for risk group 
stratification. Since 2005, a cut-off of 18 months (547 days) has been adopted by the 
Children’s Oncology Group (COG) (London et al., 2005) and was included in the 
International Neuroblastoma Risk Group (INRG) staging system in 2009 (Monclair et al., 
2009). In INRG cohort of 8,800 patients, the 5-year EFS was 42% for patients 18 months, 
compared with 82% for patients <18 months old (Cohn & Pearson et al., 2009) (Table 2). The 
5-year EFS for Stage 4 NB was significantly worse than that of non-Stage 4 disease (35% vs. 
83%). For tumors with MYCN amplification, 11q aberration, 1p aberration, and DNA ploidy 
 1, the 5-year EFS were 29%, 35%, 38%, and 55%, respectively. Patients 18 months old with 
Stage 4 MYCN amplified NB had the worst outcome (5-year EFS of 19%). In contrast, in spite 
of Stage 4 disease, the 5-year EFS was 85% for Stage 4 patients younger than 18 months with 
tumor DNA ploidy 1. In relation to Stage 4S disease, MYCN amplification reduced EFS 
from 82% to 41%, and within the MYCN non-amplified group, 11q aberration decreased EFS 
from 86% to 38% (Ambros et al., 2009). 
Moreover, in addition to disease progression on therapy, metastatic response to therapy 
measured by semi-quantitative metaiodobenzylguanidine (MIBG) score identifies a 
subgroup of ultra-high-risk patients. In a study of 75 patients, patients with MIBG score >2 
after 4 cycles of induction therapy had significantly lower 5-year EFS than those with MIBG 
score 2 (11% vs. 39%) (Matthay et al., 2003b). A recent study of over 250 patients reported a 
3-year EFS of 8.3% in patients with a MIBG score >5 post-induction, compared with EFS of 
42% in patients with MIBG score  2 (Yanik et al., 2010). High ferritin levels in Stage 4 
patients 18 months also reduced 5-year EFS from 48% to 21% for MYCN non-amplified 
tumors and from 28% to 19% for MYCN amplified tumors (Cohn & Pearson et al., 2009). 
While the majority of disease recurrences occur in high-risk patients, a small percentage of 
relapsed patients had localized NB at diagnosis and subsequently present with local or 
metastatic relapse. Factors predictive of relapse in localized NB include the presence of 
image-defined risk factors (IDRF), tumor histology, MYCN amplification, 1q and 11q 
aberration, and ALK overexpression. In the INRG pretreatment risk classification system, 
patients with localized NB and IDRF (Stage L2; 5-year EFS of 78%) have significantly worse 
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outcome than those without IDRF (Stage L1; 5-year EFS of 90%) (Monclair et al., 2009). Non-
Stage 4 patients with MYCN amplified tumors have a 5-year EFS of 46%, compared with 
MYCN non-amplified tumors with a 5-year EFS of 87% (Table 2). Within the MYCN non-
amplified cohort, the EFS of patients with 11q aberration and/or undifferentiated histology 
is significantly lower than those without these features (61% vs. 80%)(Cohn & Pearson et al., 
2009). Specifically, for patients with stroma-poor localized resectable tumors, the presence of 
1q gain and absence of 7p gain may predict relapse (Pezzolo et al., 2009). Furthermore, high 
ALK protein expression, though uncommon, may be prognostic in Stage 1 and 2 patients. 
Six of eight Stage 1 and 2 patients with high wild-type ALK expression experience relapse 
(Parodi et al., 2011). 
 
 5-year EFS ± SE (%) 
 Yes No 
Age 18 months 42 ± 1 82 ± 1 
Stage 4 35 ± 1 83 ± 1 
MYCN amp.   
all stages 29 ± 2 74 ± 1 
non-Stage 4 46 ± 4 87 ± 1 
Stage 4S 41 ± 9 82 ± 2 
Stage 4 & age 18 months 19 ± 3 48 ± 5 
Stage 4 & ploidy >1  85 ± 3 
11q aberration   
all patients 35 ± 5 68 ± 3 
non-Stage 4 & MYCN non-amp. 61 ± 11 80 ± 16 
Stage 4S & MYCN non-amp. 38 ± 30 87 ± 7 
1p 38 ± 3 74 ± 2 
DNA ploidy  1 55 ± 2 76 ± 1 
Table 2. EFS by prognostic factors in a cohort of 8,800 patients (Cohn & Pearson et al., 2009) 
Furthermore, MYCN amplification, and lumbar puncture at diagnosis were found to be 
significant risk factors for CNS recurrences in a report of 434 Stage 4 NB patients (Matthay et 
al., 2003a). In another study of 251 Stage 4 patients, lumbar puncture and elevated serum 
lactate dehydrogenase (LDH) were reported to be risk factors (Kramer et al., 2001). In these 
two studies, 28% to 36% of the patients with CNS recurrence had a lumbar puncture during 
diagnosis. As for late relapse beyond 5 years, a multivariate analysis of 422 patients 
demonstrated a relative risk of 10.5 for late relapse in patients >12 months with Stage 4 
disease at diagnosis, and a relative risk of 4.2 for those with prior relapse (Cotterill et al., 
2001). For patients who remained in first remission 5 years from diagnosis, the 10-year 
progression-free survival (PFS) for patients >12 months with Stage 4 disease at diagnosis 
was lower for other children (88% vs. 98%). 
3.1 Detection of disease recurrence 
A multitude of follow-up studies have been used to detect disease recurrence. These include 
imaging with ultrasonography, computed tomography (CT), magnetic resonance imaging 
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(MRI), bone scan, MIBG scan and positron emission tomography (PET), as well as bone 
marrow examination and urine catecholamines. The choice of tests depends on whether the 
patient presents with symptoms and signs indicative of the location of relapse, and therefore 
guide the studies to be performed. However, when surveillance studies are undertaken to 
detect asymptomatic relapse, a number of factors including the risk of relapse, as well as the 
sensitivity/specificity, invasiveness, and the cost of the studies will need to be taken into 
consideration. 
3.2 Locoregional disease 
CT is commonly the test of choice for imaging locoregional recurrence in the thorax (Figure 
1), abdomen, and pelvis (Brisse et al., 2011), especially in high risk patients who have 
received local radiotherapy, and the radiation dose from CT is relatively small compared 
with that from radiotherapy. For patients with low- and intermediate-risk NB, ultrasound of 
the abdominal and pelvic region could be considered the first imaging examination to avoid 
radiation exposure from CT, particularly when there is a low index of suspicion of relapse. 
MRI provides effective imaging without radiation, but it is limited by availability, cost, and 
the need for sedation in young children. However, for paraspinal tumors with intraspinal 
extension, MRI is recommended for better visualization of the spinal cord, nerve roots, and 
the subarachnoid space (Sofka et al., 1999). MIBG scintigraphy, which is routinely used to 
detect osteomedullary recurrence, will also demonstrate local recurrence (Figure 1). 
3.3 Metastatic disease 
Detection of metastases is an integral component of monitoring for NB recurrence, as >95% 
of relapses are metastatic, and bone and bone marrow are the most common metastatic sites. 
MIBG scintigraphy is an accurate method for detecting osteomedullary metastases (Figure 
1) as there is no physiological uptake of MIBG in bone or bone marrow. MIBG, an analog of 
norepinephrine and a guanethidine derivative, is taken up and stored in NB cells expressing 
the norepinephrine transporter and is radio-iodinated for imaging use (Boubaker & Bischof 
Delaloye, 2008). MIBG scan has a reported sensitivity and specificity of 88% and 83%, 
respectively (Vik et al., 2009). In comparison, 99mTc-technetium bone scan is reported to have 
a sensitivity of 75% and specificity of 50% for the detection of skeletal metastases (Jacobs et 
al., 1990). As a result, 123I-MIBG imaging has superseded the use of bone scan for 
demonstrating bone metastases, with the exception of tumors that are not MIBG-avid (Brisse 
et al., 2011). Approximately 10% of NB tumors do not concentrate MIBG (Carlin et al., 2003). 
False-negative MIBG scan has been observed when only a small amount of tumor cells are 
present in the bone marrow (Kushner et al., 2003b). Hence, bilateral bone marrow biopsy is 
still recommended in order to exclude bone marrow metastases (Matthay et al., 2010). Small 
hepatic lesions may not be detected by MIBG due to the high physiological uptake in the 
liver and are better depicted by ultrasound, CT or MRI (Brisse et al., 2011). 
18Fluorine-deoxyglucose (FDG) PET scan, which measures the metabolic characteristics of 
cells, has also been used for detecting NB. Compared with MIBG, FDG-PET was reported to 
be superior in the evaluation of small soft tissue lesions and Stage 1 and 2 tumors. However, 
FDG-PET was found to be less sensitive than MIBG in high-risk disease as MIBG was more 
sensitive than FDG-PET in the detection of bone metastases (Sharp et al., 2009; Taggart et al., 
2009). FDG-PET is also limited by the high physiologic uptake of FDG in the brain and can 
hide skull lesions. Nonetheless, FDG-PET may have a role in monitoring MIBG-negative 
disease. 
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Top left: CT chest shows widespread mediastinal and hilar lymphadenopathy (asterisks) with 
compression of the left main bronchus (arrow) from distant metastases of recurrent abdominal NB. 
Patients presented with shortness of breath. Top right: CT brain shows multiple nodular enhancing 
leptomeningeal deposits in the suprasellar cistern (black arrow) with encasement of the Circle of Willis 
(∆) and middle cerebral arteries bilaterally (white arrows) in a NB patient, who presented with 
increasing drowsiness at the time of isolated CNS relapse. Bottom left: MIBG scan demonstrates a large 
local recurrence (asterisk) in the left abdomen, with mixed areas of low and intense MIBG uptake. There 
are also multiple small foci of mild to moderate MIBG uptake in the mesentery and para-aortic locations 
(▲). Bottom right: MIBG scan shows skeletal metastases in both proximal humeri (▲) and spread to the 
left axillary lymph nodes (∆). 
Fig. 1. Imaging of NB disease recurrence. 
NB patients with symptoms and signs suggestive of CNS metastases are best imaged with 
CT and/or MRI of the brain and spinal cord for parenchymal brain lesions and 
leptomeningeal spread (Figure 1). While MIBG can be positive with CNS involvement, the 
sensitivity of MIBG for CNS metastases is low. Matthay et al. reported that MIBG scans were 
negative in half of the patients with CNS recurrences (Matthay et al., 2003a). Difficulty in 
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distinguishing cerebral lesions from skull lesions, especially without the help of SPECT 
images to localize a lesion, and the presence of meningeal disease without bulky lesions 
make MIBG unsuitable for evaluating CNS metastases. 
3.4 Surveillance of asymptomatic relapse 
The risk of relapse, the sensitivity and specificity of a specific investigation for detecting 
relapse, dose of radiation of an imaging study, invasiveness of a test, need of general 
anesthesia, and the cost of a study are all important factors to be considered when 
determining a surveillance protocol to detect asymptomatic relapse. For patients with high-
risk NB, early detection of recurrence will likely result in better response to salvage therapy 
than in the setting of bulky metastatic disease. However, it is unclear whether early 
detection of recurrence prior to the onset of symptoms will lead to increased cure and 
whether a specific subgroup of NB patients will benefit from surveillance regimens that 
identify early relapse. 
3.4.1 Surveillance of low and intermediate-risk NB 
Patients with low probability of relapse should be followed up with tests that are non-
invasive, require minimal or no sedation, and involve no or the lowest doses of radiation. 
Since children are known to have the highest inherent sensitivity to the carcinogenic effects 
of ionizing radiation (Brody et al., 2007), patients with low- and intermediate-risk NB who 
have no prior exposure to radiotherapy should be monitored with ultrasound and 123I-
MIBG. The radiation dose of 123I-MIBG is 10% of that of 131I-MIBG (Bombardieri et al., 2003). 
The INRG Task Force recommends post-therapy surveillance MIBG scan at 6-month 
intervals for 1 year for low-risk Stage 2 patients, and for 2 years for intermediate-risk 
patients (Matthay et al., 2010). While the measurement of urine catecholamines is a non-
invasive test, it is not used as a follow-up investigation due to its poor sensitivity in 
detecting relapse. The sensitivity of urine catecholamines is only 23% for detecting isolated 
local recurrence (Simon et al., 2003). 
3.4.2 Surveillance of high-risk NB 
High-risk NB patients have a significantly higher risk of relapse with a 2-year EFS survival 
of 46% (Matthay et al., 2009b). Most patients undergo surveillance studies every 3 months 
until 3 years from diagnosis. CT, MIBG, and bone marrow examination are the most 
frequently utilized to monitor for disease recurrence. After this critical period, the frequency 
and type of follow-up studies are generally tailored to the likelihood of relapse of individual 
patients. 
In a recent study of 91 high-risk patients with asymptomatic relapse, 123I-MIBG scan was 
reported to have the highest sensitivity (82%) of detecting unsuspected relapse, compared 
with bone scan, bone marrow examination, CT (head), CT (chest/abdomen/pelvis), and 
urine catecholamines, with sensitivities of 27%, 28%, 22%, 29%, and 18%, respectively 
(Kushner et al., 2009). 123I-MIBG scan was the sole indicator of unsuspected relapse in 27% of 
patients, whereas CT chest/abdomen/pelvis was the only positive test in 6% of patients, CT 
head in 3% of patients, bone marrow histology in 4.5% of patients, bone scan in 3% of 
patients, and urine catecholamines in none of the patients. However, 123I-MIBG scan failed 
to reveal unsuspected relapse in the bone marrow in 25% of patients, in extracranial soft 
tissue in 21% of patients, and in head/orbits in 13% of patients. This study confirms the 
limitations of MIBG to detect low levels of bone marrow infiltration, small liver lesions, and 
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CNS metastases. In addition, urine catecholamine levels have limited use in diagnosing 
early recurrence with small tumor burden. 
3.4.3 Surveillance of minimal residual disease 
Minimal residual disease (MRD) in NB refers to the small number of circulating tumor cells 
present in the bone marrow, peripheral blood, or peripheral blood stem cells. Although 
histological examination of bone marrow is considered the gold standard for assessing bone 
marrow metastases, this conventional tool has a detection level of only 1% tumor cells (N.K. 
Cheung et al., 1997) and does not have sufficient sensitivity to detect MRD. Significant effort 
has therefore been directed towards the development of MRD detection methods in the last 
two decades. The ability to measure occult tumor cells is important for increasing the 
sensitivity of detecting metastases at diagnosis, evaluating response during treatment, and 
detecting early relapse post therapy. 
The three main MRD detection techniques are immunocytology (IC), quantitative reverse 
transcriptase polymerase chain reaction (QRT-PCR), and flow cytometry (FC) (Beiske et al., 
2005). For IC, both the SIOPEN Bone Marrow Committee and the INRG Task Force have 
recommended disialoganglioside (GD2) as a target cell surface antigen and have developed 
standardized protocol for IC (Beiske et al., 2009; Swerts et al., 2005). Similarly, standard 
operating procedures have been developed by the SIOPEN Research Network and INRG 
Task Force for QRT-PCR, using tyrosine hydroxylase as target mRNA (Beiske et al., 2009; 
Viprey et al., 2007). The use of multiple molecular markers in QRT-PCR to increase the 
sensitivity and specificity of MRD detection has also been investigated (I.Y. Cheung et al., 
1998; I.Y. Cheung et al., 2008; Stutterheim et al., 2009). FC has the advantage of measuring 
several antigens on single cells and can screen a large number of cells in a short time. CD9, 
CD56, CD45, CD81, anti-GD2 are the commonly used markers (Beiske et al., 2005). However, 
FC is considered to be less sensitive than IC for MRD detection in NB. 
Despite all the technological advances made in MRD detection, the clinical relevance of 
MRD remains unclear. While the majority of studies demonstrated the prognostic value of 
MRD in bone marrow and blood, the level of clinically significant MRD and the timing of 
MRD were not consistent in these studies (Burchill et al., 2001; Cai et al., 2007; I.Y. Cheung et 
al., 2003; Moss et al., 1991; Seeger et al., 2000; Stutterheim et al., 2011). The clinical utility of 
MRD in NB at various stages of therapy requires validation in large prospective multi-center 
clinical trials using standardized protocols. Which marker(s) should be exploited? What 
level of MRD is indicative of relapse? Does very early intervention based on MRD improve 
survival post relapse? Answers to these questions will no doubt influence future 
surveillance program to monitor early relapse. 
4. Survival following disease recurrence 
Long-term cure after NB relapse is considered rare. For patients treated in the 1990’s, the 5-
year post-recurrence survival is 11% (Santana et al., 2008) and the median survival is 8 
months (Lau et al., 2004). Patients who relapse within 12 to 16 months from diagnosis did 
even worse and median survival was only 2.5 months (Lau et al., 2004; Santana et al., 2008). 
Prognostic factors at diagnosis continue to have a significant impact on survival post relapse 
(London & Castel et al., 2011). In addition, a small number of patients are reported to have a 
protracted clinical course after relapse. Chronic NB may become more apparent in the next 
decade when prolonged survival with multiple recurrences is encountered with increasing 
frequency with novel therapeutics. 
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4.1 Factors predictive of survival after relapse 
Many of the factors at diagnosis that are prognostic of EFS and overall survival (OS) also 
influence OS after disease progression or relapse. As stated above, the COG uses age (<18 
months, ≥18 months), INSS stage, MYCN status, histopathology, and ploidy to assign 
patients to the appropriate level of treatment intensity at the time of diagnosis. In an INRG 
analysis of 2,266 patients who experienced first progression/relapse, the median time to 
relapse was 13 months, and 5-year OS from the time of first relapse was 20% (London & 
Castel et al., 2011). After disease progression or relapse, factors identified as most highly 
prognostic of poor OS were age ≥18 months, use of intensive multi-modality treatment at 
diagnosis, stage 4, elevated serum ferritin, elevated LDH, unfavorable histology, high MKI, 
and MYCN amplification, whereby the presence of any one of these adverse features 
doubled the risk for death post-relapse. Furthermore, time from diagnosis to first 
relapse/progression had a significant impact on survival after relapse. However, time-to-
first-relapse (TTFR) was associated with OS time in a complex non-linear relationship; 
patients with TTFR of 36 months or longer had the lowest risk of death, followed by patients 
who relapsed in the period of 0 to less than 6 months or 18 to 36 months. Patients who 
relapsed between 6 and 18 months after diagnosis had the highest risk of death. TTFR, older 
age, higher INSS stage, and MYCN amplification were independently prognostic of worse 
post relapse OS in multivariable analysis. Within the subgroup of patients with MYCN 
amplified tumors and stage 3 and 4 disease, TTFR was the most highly predictive of OS post 
relapse (London & Castel et al., 2011). 
In a retrospective study describing 781 children with NB experiencing tumor recurrence, the 
10-year OS was 6.8% after progression and 14.4% after relapse (Garaventa et al., 2009). 
Similar to the findings of London & Castel et al. (2011), the factors worsening outcome in 
univariate analysis were age >18 months, advanced stage, high LDH, MYCN amplification, 
and abdominal primary (no multivariable analysis). Most relapses occurred early (median 
7.8 months), but 86 (24%) occurred late (median 28 months). Early relapses had a more 
rapid, unfavorable course, with ~80% of deaths occurring within 2 years, whereas survival 
time was longer for late relapses. From the German protocols NB90, NB97, and NB2004 (451 
high-risk patients), Simon et al. presented data on 232 patients with NB who relapsed after 
autologous stem cell transplantation (ASCT) as part of initial treatment (Simon et al., 2011). 
MYCN amplification, early recurrence within 18 or 24 months after diagnosis, as well as 
bone marrow and lung/pleura metastasis at relapse were independently predictive of poor 
survival in multivariate analysis. Of the patients who received second-line chemotherapy, 
the 23 patients who underwent a second ASCT had better outcome than the 135 patients 
who did not have a second ASCT (3 year OS of 43.5% vs. 9.6%). 
Two previous single-institution studies in NB also showed that shorter time to first relapse 
was a significant adverse factor for survival. Lau et al. reviewed 31 patients with NB with 
relapsed disease and found that patients who relapsed less than 12 months from diagnosis, 
patients who did not receive salvage therapy, and patients with tumor MYCN amplification 
had significantly shorter survival time (Lau et al., 2004). Santana et al. addressed the study 
of disease-control intervals in 91 high-risk patients with NB (Santana et al., 2008). The 
estimated median times to disease recurrence were 18.3, 8.7, and 3.8 months for the first, 
second, and third recurrences, respectively. Patients with longer initial disease control had a 
significant post-recurrence survival advantage. This study emphasized the importance of 
knowing the intervals of disease progression as end points for the design of protocols with 
new agents. 
Ultimately, understanding the genetic differences in early versus late relapsing patients will 
facilitate selection of appropriate targeted therapy. Meanwhile, it is appropriate to perform 
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stratification of relapsed patients according to the timing of first relapse, as well as stage, 
age, and MYCN status; this is critical in certain types of study designs, such as randomized 
phase II trials, to maintain a balance of less favorable patients between treatment arms. 
4.2 Outcome of CNS recurrence 
If patients recur with neuraxis involvement, the outcome has always been considered 
ominous, either with or without treatment. The median survival from CNS recurrence 
ranged from 2 to 14 months and survival beyond 18 months was very rare (Kellie et al., 
1991; Kramer et al., 2001; Matthay et al., 2003a; Shaw & Eden, 1992). It was also suggested 
that patients with meningeal recurrence had the shortest survival (0.9 months) (Matthay et 
al., 2003a). However, CNS-directed radioimmunotherapy may improve the outcome of these 
patients (Croog et al., 2010; Kramer et al., 2010) (refer to Section 5.2 for details). 
4.3 Chronic neuroblastoma and late relapse 
Chronic or indolent NB generally refers to active NB beyond four to five years from 
diagnosis. This can arise from persistent stable disease, first recurrence followed by a 
protracted disease course with multiple recurrences or from late relapse with or without 
prolonged survival. 
4.3.1 Chronic neuroblastoma in adolescents and adults 
Indolent NB is a more common phenomenon in adolescents and adults than in children, but 
the actual number of adolescents and adults with NB is very small, since over 90% of NB 
patients are diagnosed before the of age 10 years. Despite an indolent course and the 
absence of MYCN amplification, the outcome of these patients is very poor. Of the 1,950 NB 
patients registered with the Children’s Cancer Group from 1973 to 1993, 2% of patients were 
aged between 13 and 18 years, and survival was 7% at 5 years compared with 30% survival 
in patients aged 1 to 13 years (Franks et al., 1997). Only one tumor from the older age group 
had MYCN amplification. In a report of 1116 children and 53 adolescence (age 10 -18 years), 
adolescence were also found to have worse outcome than children (10-year OS 20% vs. 39%) 
and had an indolent course post-recurrence (Conte et al., 2006). Franks et al. described 15 of 
the 16 NB patients aged between 13 and 33 years subsequently relapsed and 13 died. The 
median OS was 3.5 years, which is significantly longer than the post-relapse median 
survival of eight months in children. Moreover, in adolescents and adults, non-Stage 4 
patients have an even more protracted course following relapse than Stage 4 patients 
(median survival 7.8 vs. 2.8 years). 
4.3.2 Chronic neuroblastoma in children 
Childhood NB may follow a chronic course and has partly been attributed to improved 
salvage regimens that have become available in the last decade. Children with chronic NB 
can be separated according to the timing of relapse. In a study by Kushner et al. describing 
NB patients who were younger than 10 years old at diagnosis and had metastatic disease 
five years or more from diagnosis, 21 Stage 4 patients had first relapse <4 years from 
diagnosis (Kushner et al., 2002). All 21 patients had a second recurrence and 13 had a third 
recurrence. Seventeen (81%) died of NB between 5 and 9.8 years from diagnosis, and four 
were alive with disease 5.6 to 7.8 years from diagnosis. The study also included Stage 4 
patients who presented with late first relapse (4.3 to 13 years from diagnosis). This group of 
late relapse patients appears to have an even more chronic course. Three of the nine patients 
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died of NB at 7.3 to 10.4 years from diagnosis, three were alive with disease 6.7 to 14.1 years, 
and three were in second remission 6.8 to 19.5 years. Multiple recurrences were also 
described by Santana et al. (Santana et al., 2008). In a cohort of 66 relapsed NB patients, 12% 
had one recurrence (median 15.7 months from diagnosis), 21% had two recurrences (median 
7.2 months from last relapse), and 67% had at least three recurrences (median 3.5 months). 
The interval between each successive recurrence decreased. 
4.3.3 Late relapse 
First relapse occurring more than five years from initial diagnosis is uncommon and is 
observed in 3% of NB patients who remain in remission for the first five years. In a study 
where 406 remission patients were followed up >5 years from diagnosis, 18 patients 
relapsed and 14 of these were late first recurrences (Cotterill et al., 2001). Only two patients 
were alive at the time of report. A literature review described 30 cases of late NB recurrences 
(published between 1950 and 1990) (Cervera et al., 1990). In 29 patients, relapse occurred 
between 5 and 16 years from diagnosis. The outcome was only known in 24 patients, of 
whom 17 died of NB at 6.5 to 24.7 years from diagnosis. One case was exceptional in that a 
man, who was 29 years old at diagnosis, relapsed 52 years later (Mir et al., 1987). Kushner et 
al. also reported a man, who relapsed 38 years after he was diagnosed at age 8 years 
(Kushner et al., 2002). 
5. Therapeutic strategies for relapsed NB 
Extensive effort has been put into the development of drugs to treat high-risk NB. The most 
recent advance is the use of anti-GD2 immunotherapy to eradicate MRD (Yu et al., 2010). 
However, at this point of time, 50% of high-risk NB patients will relapse after receiving 
conventional treatment without immunotherapy. Current salvage regimens can induce 
response or arrest disease progression in 60% of relapsed patients (Lau et al., 2004), but to 
date no salvage treatment regimens are known to be curative. A number of novel agents 
with anti-NB activities are currently under investigation and are mostly available to 
relapsed patients who are eligible for specific phase I/II clinical trials. 
5.1 Conventional chemotherapeutics 
Intensive regimens using conventional chemotherapeutic agents were used in relapsed NB 
patients in the 1990’s, and they include various combinations of high doses of carboplatin, 
cisplatin, cyclophosphamide, ifosfamide, doxorubicin, and etoposide (Alvarado et al., 1997; 
Campbell et al., 1993; Kreissman et al., 1997). Although these treatments achieved responses 
in 35 to 50% of patients, they were accompanied by unacceptably high toxicities with no 
improvement in long-term outcome and are rarely indicated in current settings. 
Myeloablative therapy is also rarely indicated for the same reason, with the exception of 
metastatic relapse in patients with low and intermediate-risk NB, who may be salvaged with 
frontline myeloablative regimen used for high-risk disease. However, the use of moderate 
dose of conventional chemotherapy in combination with new agents is an important means 
of assessing new agents in phase I/II studies. 
5.2 Palliative radiotherapy 
While radiotherapy (RT) cannot cure relapse, it provides rapid and effective symptom 
control and palliation for skeletal, soft tissue, and CNS metastases. NB often remains 
radiosensitive at relapse. Palliative RT is given for bone pain, obstructive symptoms from 
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soft tissue mass and neurological symptoms from CNS disease. 200 to 300cGy is delivered 
for each fraction and the number of fractions given depends on response (Caussa et al., 2011; 
Paulino, 2003). The median total RT dose is around 2000cGy. RT can achieve a response rate 
of 63 to 79% in skeletal metastases, 67 to 84% in soft tissue sites, and 44 to 80% in CNS 
metastases (Caussa et al., 2011; Halperin & Cox, 1986; Paulino, 2003). 
5.3 Second-line chemotherapy 
Further dose intensification with conventional chemotherapeutics is not a practical option 
with disease recurrence. Second line chemotherapies with mild to modest toxicities that 
have not been included in frontline treatment are often considered for salvage. Topotecan, 
irinotecan, temozolomide are commercially available drugs. Other agents such as 
fenretinide and vorinostat are still undergoing clinical trials for NB treatment. 
5.3.1 Topoisomerase I inhibitors 
Over the past decade, topotecan and irinotecan, both topoisomerase I inhibitors with proven 
anti-NB activity, have been frequently used in relapsed NB. Targeting the DNA-relaxing 
enzyme topoisomerase I results in failure of DNA re-ligation during DNA replication and 
repair. In a phase II trial, partial responses (PR) or better were observed in 32% of the 57 
relapsed patients receiving topotecan and cyclophosphamide and in 19% of the 62 patients 
in the topotecan alone group. While the topotecan/cyclophosphamide group had a 
significantly better 3-year PFS (10% vs. 0%), there was no difference in 3-year OS (17% vs. 
14%) (London et al., 2010). The combination of topotecan and cyclophosphamide has been 
the most extensively utilized salvage regimen, and 60% of relapsed patients are expected to 
experience grade 3 or 4 hematological toxicity. Vincristine or etoposide have also been 
added as a third drug to topotecan/cyclophosphamide, and PR or better were obtained in 
52% and 61% of relapsed patients, respectively (Kushner et al., 2010; Simon et al., 2007). 
In many cases, irinotecan is combined with temozolomide. A phase II study of irinotecan/ 
oral temozolomide demonstrated a response rate of 19% and stable disease (SD) of 56% in 
relapsed patients (Bagatell et al., 2011). Diarrhoea is a common side effect of irinotecan, and 
Grade 3 or 4 diarrhoea was reported in 6% of patients. Oral irinotecan/temozolomide, 
which has the benefit of home administration and reduced costs, has also been tested, with 
50% of patients achieving response or stable disease (Wagner et al., 2009). High dose 
carboplatin/irinotecan/temozolomide had a response rate of 68% (Kushner et al., 2011). 
5.3.2 Fenretinide 
Fenretinide (N-4-hydroxyphenyl retinamide, [4-HPR]) is a synthetic retinoid with cytotoxic 
and growth inhibitory effects on NB cell lines. Unlike 13-cis- and all-trans-retinoic acids, 
fenretinide does not induce cellular differentiation, but induces apoptosis (Di Vinci et al., 
1994). The mechanisms of action include de novo ceramide synthesis, generation of reactive 
oxygen species (Maurer et al., 1999), anti-angiogenesis (Ribatti et al., 2003), and increased 
natural-killer cell activity (Villa et al., 1993). Phase I trials of oral fenretinide in relapsed NB 
patients demonstrated SD in 43% to 77% of patients (Garaventa et al., 2003; Villablanca et al., 
2006). One NB patient had a complete response (CR). However, capsule formulation of 
fenretinide has poor bioavailability and wide interpatient variation, and the large capsules 
present a major challenge for children to ingest. LYM-X-SORB, a novel organized lipid 
matrix, can increase the oral bioavailability of fenretinide (Maurer et al., 2007). A phase I 
study of fenretinide/LYM-X-SORB oral powder formulation in NB patients is underway. 
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5.3.3 Vorinostat 
Vorinostat (suberoylanilide hydroxamic acid, [SAHA]) is an oral histone deacetylase 
(HDAC) inhibitor. HDAC inhibition leads to histone acetylation, opening of chromatin 
structure, and reactivation of previously silenced genes (Johnstone, 2002). In NB, HDAC 
inhibitors have been shown to induce apoptosis and impair VEGF production (Muhlethaler-
Mottet et al., 2008), restore the p53 pathway (Condorelli et al., 2008), synergize with retinoic 
acid to inhibit growth (Coffey et al., 2001), and enhance RT (S. Mueller et al., 2011). In a 
phase I trial of vorinostat, one CR was observed in a NB patient receiving vorinostat in 
combination with 13-cis-retinoic acid (Fouladi et al., 2010). 
5.4 Immunotherapy 
GD2, disialoganglioside, is the most common tumor-associated antigen targeted in NB 
immunotherapy. GD2 is an ideal target as it is a ubiquitous and abundant surface glycolipid 
that is present on NB cells but in normal tissue except for neurons. The three main anti-GD2 
monoclonal antibodies (MoAb) are 3F8, ch14.18, and hu14.18-IL-2. Tumor cells are killed via 
complement activation and antibody-dependent cell-mediated cytotoxicity (ADCC) that can 
be augmented by cytokines, e.g. interleukin-2 (IL-2) and GM-CSF (Hank et al., 1990; Imai et 
al., 2005; B.M. Mueller et al., 1990). Chimeric antibody Ch14.18/IL-2/GM-CSF 
immunotherapy is effective against MRD in the post-consolidation setting, as shown in a 
recent phase III randomized trial in primary NB (Yu et al., 2010). In recurrent NB, 
unsustained response to immunotherapy is restricted to non-bulky disease in the bone 
marrow and small MIBG-avid lesions. Common side effects include pain, capillary leak 
syndrome, hypotension, and allergic reaction. 
3F8 is a murine MoAb and is the first MoAb to be studied in NB patients (N.K. Cheung et 
al., 1987). In a phase II study of 3F8/GMCSF, CR in five of 10 patients was restricted to the 
bone marrow and all developed progressive disease at other sites (Kushner et al., 2001). 
Similar results were seen in a phase II study of humanized 14.18-IL-2, a fusion protein of 
humanized 14.18 anti-GD2 MoAb linked to IL-2 (Shusterman et al., 2010). Of the 20 patients 
with small disease burden, CR was achieved in five patients, three of whom had bone 
marrow disease only by histology at relapse, one had a single MIBG-avid lesion, and one 
had both bone marrow and bone disease. 
Unlike high-risk patients, patients who have locoregional NB and relapse with metastatic 
disease may be salvaged with immunotherapy. Kushner et al. reported three of five patients, 
who were initially treated with surgery alone for low-risk NB and subsequently relapsed 
with metastatic disease, were in CR at four to seven years (Kushner et al., 2003a). These 
patients received an intensive salvage regimen containing intensive chemotherapy, 3F8 
MoAb, 131I-3F8, local RT, and 13-cis-retinoic acid. 
5.5 Radionuclide therapy  
MIBG is taken up by 90% of NB tumors. MIBG labeled with therapeutic isotope 131I is used 
to deliver target specific RT in NB for >20 years. 131I-MIBG therapy is generally well 
tolerated, except for myelosuppression that may require stem cell support in heavily 
pretreated patients (DuBois et al., 2004). MIBG monotherapy achieved responses in up to a 
third of relapsed patients at doses 12 mCi/kg, but with no long-term cure (DuBois & 
Matthay, 2008). In a large phase II trial of 164 patients receiving 12 to 18 mCi/kg of 131I-
MIBG, the overall response rate was 36% and SD rate was 36%, and the 2-year OS was 29% 
(Matthay et al., 2007). The additional benefits of dose intensification with tandem 131I-MIBG 
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infusions (Matthay et al., 2009a) and of including 131I-MIBG with myeloablative therapy 
requires further studies (Matthay et al., 2006). 
131I-MIBG therapy may be enhanced with radiosensitizers such as cisplatin (Mastrangelo et 
al., 1997) and topotecan (Gaze et al., 2005) or with non-carrier added radiolabeled MIBG. 
Conventional preparation of 131I-MIBG has large quantities of unlabeled or cold (non-
radioactive) MIBG in the final formulation. Saturation of the norepinephrine transporter by 
unlabeled MIBG reduces the efficacy while increasing the side-effects. This can be 
circumvented by using the Ultratrace solid-phase preparation technique to synthesize non-
carrier added radiolabeled MIBG (Ultratrace 131I-MIBG). This novel formulation resulted in 
greater tumor uptake and efficacy in NB xenografts (Barrett et al., 2010). The increased 
uptake and retention of Ultratrace 131I-MIBG may have therapeutic benefit by allowing 
further intensification of MIBG therapy. 
5.6 Targeted therapies 
Targeted therapies with potential anti-NB activities include small molecule inhibitors 
against ALK (anaplastic lymphoma kinase), aurora A kinase, trk tyrosine kinase, Akt/PI3-
kinase, and EGFR, and monoclonal antibodies against VEGF, IGF-1, and TRAIL receptor. 
5.6.1 ALK inhibition 
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase and was identified as a NB 
predisposition gene (Mosse et al., 2008). ALK somatic mutations and amplification are found 
in 8% of primary NB. Of interest, a subset of tumors expressing high mRNA levels of wild-
type ALK have similar genotype and poor clinical outcome to tumors with ALK 
mutations/amplification (Schulte et al., 2011). Preclinical data show that ALK inhibition 
diminishes growth in cells with ALK mutations, as well as in cells overexpressing wild-type 
ALK (Janoueix-Lerosey et al., 2008). Hence, ALK inhibitors may potentially be effective in 
NB tumors expressing high levels of ALK. A phase I/II trial of a small molecule inhibitor of 
ALK is in progress. 
5.6.2 Anti-angiogenesis 
NB is a highly vascular tumor and tumor angiogenesis is associated with metastatic disease 
and poor outcome (Meitar et al., 1996). Bevacizumab (MoAb against vascular endothelial 
growth factor (VEGF)), did not lead to any objective responses when used as a single agent 
in children with refractory solid tumors (Glade Bender et al., 2008). The efficacy of 
bevacizumab in combination with irinotecan/temozolomide and with the radiolabeled 131I-
3F8 antibody in relapsed NB is currently being investigated. 
5.6.3 TRK inhibition 
TrkB, a member of the Trk (NTRK) neurotrophin tyrosine kinase receptors, is highly 
expressed in unfavorable NB (Brodeur et al., 2009; Nakagawara et al., 1994). TrkB 
overexpression results in increased chemoresistance in NB cells (Ho et al., 2002). 
Lestaurtinib (CEP-701), a selective Trk tyrosine kinase inhibitor, has anti-tumor activity in 
NB xenograft models, both as a single agent and in combination with 
topotecan/cyclophosphamide and with irinotecan/temozolomide (Iyer et al., 2010). In a 
phase I trial of lestaurtinib, two PR and nine SD were reported in 46 patients with refractory 
NB (Minturn et al., 2011). 
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5.7 Treatment of CNS relapse 
The outcome of CNS recurrence is dismal with conventional chemotherapeutic agents. The 
use of CNS-directed radioimmunotherapy (RIT) may improve the prognosis of this group of 
patients. RIT enables the targeted delivery of RT to tumor cells (Kramer et al., 2007). In a 
retrospective analysis of 14 patients who received craniospinal irradiation together with 
irinotecan as a radiosensitizer, followed by intra-Ommaya (IO) RIT (131I-8H9 or 131I-3F8), 10 
were alive with no CNS disease at 15.2 to 62.7 months from CNS relapse, three were alive 
with disease at 24.6 to 30.2 months, and one died from other cause but without disease at 
21.9 months (Croog et al., 2010). This is in contrast with the 12 patients, who only received 
whole/partial brain or partial spine radiotherapy and all succumbed 4.2 to 23.9 months 
later. In addition, the same group treated 21 patients with CNS recurrences with an 
intensive regimen containing IO RIT (131I-8H9 or 131I-3F8) with promising results (Kramer et 
al., 2010). Seventeen patients were alive without CNS disease at 7 to 74 months post CNS 
relapse. In addition to IO RIT, patients also received CSI with irinotecan, 
irinotecan/temozolomide/carboplatin, systemic immunotherapy (anti-3F8 with GMCSF), 
and maintenance treatment with 13-cis-retinoic acid and oral temozolomide. The long-term 
treatment consequences of CNS directed RIT are yet to be evaluated. 
The use of IO topotecan has also been described in a NB case report of isolated CNS 
metastases. This patient, who received both IO and IV topotecan, had a CR of both 
parenchymal and leptomeningeal disease and was progression-free for 18 weeks 
(Sirachainan et al., 2008).  
6. Conclusion 
Although long-term disease-free survival after recurrent NB remains extremely poor, 
salvage regimens in the recent era have altered the natural disease course and prolong post-
relapse survival, with a small subset of chronic patients experiencing multiple recurrences 
or non-remitting disease. However, it is difficult to predict response to salvage therapy and 
survival time post relapse. Knowledge in this area is limited. Which patients should be 
offered multi-modality treatment and which patients should receive oral agents with 
minimal toxicity? How can we ensure quality of life is not jeopardized by unrealistic 
expectations? These are difficult questions clinicians must face whenever a child with NB 
relapses.  
Furthermore, surveillance for disease recurrence can cause significant emotional and 
financial burden. Can detection of early asymptomatic relapse improve quality of life or 
change long-term survival? Can the detection of early molecular relapse by monitoring 
MRD improve response to salvage therapy and increase survival? What is a clinical 
significant MRD level? Further research is needed to provide answers to these questions to 
facilitate development of effective surveillance protocols. 
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